EnzymeBioSystems (OTCBB:ENZB) can be better termed as a small firm with a big and innovative Pharma mentality. Ed Zimmerman, III CFO stated that the pharmaceutical industry has changed considerably over the past decade. If investors look at the past, big companies will spend a massive amount of dollars on just completing its research on new pharmaceutical compounds. However, it is not the same scenario in present pharmaceutical industry.
Zimmerman of EnzymeBioSystems said that the key here is acquisitions. The big Pharma companies look out for more economical ways to expand their market share in the industry. They find it wiser to hunt for smaller companies and acquire them. In a way, they don’t need to spend a huge amount on R&D. Also, they get access to a firm that develops and market innovative novel products. The affiliates and management of EnzymeBioSystems have more than fifty years of extensive experience working for big Pharma companies. The experience is an asset that assists the company to function with the knowledge it gained from big Pharma firms.
Amooranin is the lead pharmaceutical product of EnzymeBioSystems (OTCBB:ENZB). The management said that the product holds the potential to be used in the prevention of breast cancer. The team is working to get the necessary trials so that it can apply for an Investigational New Drug application for Amooranin. The team has completed with sourcing tasks of the pre-clinical product batch. It is now negotiating with CRO on the two species animal trials.
The management view
Gary Rojewski, the CEO of EnzymeBioSystems (OTCBB:ENZB), said that the management believes to have selected the right scientific team. They can efficiently work on required animal trials. The company will continue to update on progress reports in coming period. In case, there is a major development, the management will file a Form 8-K and go for a press release to update valued shareholders.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: